rs4553808
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(A;A) | 0 | normal |
(A;G) | possibly lower risk for myasthenia gravis | |
(G;G) | 0.05x (decreased) risk for myasthenia gravis |
Reference | GRCh38 38.1/141 |
Chromosome | 2 |
Position | 203866282 |
Gene | CTLA4 |
is a | snp |
is | mentioned by |
dbSNP | rs4553808 |
dbSNP (classic) | rs4553808 |
ClinGen | rs4553808 |
ebi | rs4553808 |
HLI | rs4553808 |
Exac | rs4553808 |
Gnomad | rs4553808 |
Varsome | rs4553808 |
LitVar | rs4553808 |
Map | rs4553808 |
PheGenI | rs4553808 |
Biobank | rs4553808 |
1000 genomes | rs4553808 |
hgdp | rs4553808 |
ensembl | rs4553808 |
geneview | rs4553808 |
scholar | rs4553808 |
rs4553808 | |
pharmgkb | rs4553808 |
gwascentral | rs4553808 |
openSNP | rs4553808 |
23andMe | rs4553808 |
SNPshot | rs4553808 |
SNPdbe | rs4553808 |
MSV3d | rs4553808 |
GWAS Ctlg | rs4553808 |
GMAF | 0.152 |
Max Magnitude | 0 |
? | (A;A) (A;G) (G;G) | 28 |
---|---|---|
|
rs4553808, also known as A/G-1661, is a SNP in the upstream activator sequence of the cytotoxic T lymphocyte associated antigen-4 CTLA4 gene. This gene encodes the CD152 antigen.
A study of 165 Swedish myasthenia gravis patients concluded that the rs4553808(G;G) homozygotes had an odds ratio of 0.05 (CI: 0.00286-0.874, p=0.0023) for the disease compared to healthy individuals, while the rs4553808(G) allele showed a less dramatic reduction in risk, with an odds ratio of 0.578 (CI: 0.373-0.897, p=0.015).[PMID 18088253]
[PMID 19438904] Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease
[PMID 22178694] Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematological malignancies
[PMID 15452244] Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.
[PMID 17825114] Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population.
[PMID 18528295] Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
[PMID 19609446] CTLA4 autoimmunity-associated genotype contributes to severe pulmonary tuberculosis in an African population.
[PMID 19622768] CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer.
[PMID 20352109] Association of the CTLA4 gene with Graves' disease in the Chinese Han population.
[PMID 21228734] Genetic variation associated with bortezomib-induced peripheral neuropathy.
[PMID 22418270] Polymorphisms in cytotoxic T lymphocyte associated antigen-4 influence the rate of acute rejection after renal transplantation in 167 Chinese recipients.
[PMID 23480667] Cytotoxic T-Lymphocyte Antigen-4 Genetic Variants and Risk of Ewing's Sarcoma
[PMID 24015180] CTLA4 Gene Polymorphisms Influence the Incidence of Infection after Renal Transplantation in Chinese Recipients
[PMID 24313821] Association of CTLA-4 Gene Polymorphism with End-Stage Renal Disease and Renal Allograft Outcome
[PMID 23628397] Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients
[PMID 23261408] -1722T/C polymorphism (rs733618) of CTLA-4 significantly associated with systemic lupus erythematosus (SLE): a comprehensive meta-analysis.
[PMID 24631737] Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis
[PMID 25900029] SNP-SNP interactions of immunity related genes involved into CD28/B7 pathway with susceptibility to invasive ductal carcinoma of the breast
[PMID 29264740] CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
[PMID 29794444] Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies.